Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026

Phase 3amlenetugPositive

AI Analysis

Summary

Lundbeck will present late-breaking Phase III MASCOT trial data on amlenetug for multiple system atrophy at MDS 2026, characterizing the clinical profile and participant diversity from the ongoing global trial.

Clinical Trial Data

Phase

Phase III

Outcome Details

Late-breaking oral presentation of Phase III MASCOT trial data

Importance:6/10

Sentiment:

0.50

movement disordersmultiple system atrophyParkinson's diseasePhase IIIconference presentationMDS 2026

Related Companies

$HLUYY

Read the original article

Published by PR Newswire Biotech on October 2, 2026 6:31 AM

Read Original